• Je něco špatně v tomto záznamu ?

Stereoselective interactions of warfarin enantiomers with the pregnane X nuclear receptor in gene regulation of major drug-metabolizing cytochrome P450 enzymes

A. Rulcova, I. Prokopova, L. Krausova, M. Bitman, R. Vrzal, Z. Dvorak, J. Blahos, P. Pavek

. 2010 ; 8 (12) : 2708-2717.

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12027375

UNLABELLED: Background: Warfarin, an antagonist of vitamin K, is an oral coumarin anticoagulant widely used to control and prevent thromboembolic disorders. Warfarin is clinically available as a racemic mixture of R- and S-warfarin. The S-enantiomer has three to five times greater anticoagulation potency than its optical congener. Recently, vitamin K2 function has been proposed via the pregnane X receptor (PXR) in osteocytes. PXR acts as a xenobiotic sensor that controls expression of many genes involved in drug/xenobiotic metabolic clearance. OBJECTIVE: The aim was to examine whether enantiomers of warfarin stereoselectively interact with PXR to up-regulate main drug/xenobiotic-metabolizing enzymes of the cytochrome P450 superfamily. METHODS: Interactions of warfarin enantiomers with PXR were tested by gene reporter assays and time-resolved fluorescence resonance energy transfer technology (TR-FRET) ligand binding assay. Up-regulation of PXR-target gene mRNAs by warfarin enantiomers was studied using semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) in primary human hepatocytes. RESULTS: We found that R-warfarin interacts with the PXR nuclear receptor. Consistently, R-warfarin significantly induced CYP3A4 and CYP2C9 mRNAs in cultures of primary human hepatocytes or in LS174T intestinal cells. On the other hand, S-warfarin is a less potent inducer of PXR-target genes in human hepatocytes and activates PXR only at supraphysiological concentrations. In addition, we showed that racemic 10- and 4'-hydroxywarfarins are also highly potent PXR ligands and inducers of CYP3A4 and CYP2C9 mRNA in human hepatocytes. CONCLUSION: We showed that R-warfarin can significantly up-regulate major drug-metabolizing enzymes CYP3A4 and CYP2C9 in the liver and thus may cause drug-drug interactions (DDI) with co-administered drugs. The results warrant reconsideration of racemic warfarin usage in clinics.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12027375
003      
CZ-PrNML
005      
20250318105631.0
007      
ta
008      
120816s2010 enk f 000 0#eng||
009      
AR
024    7_
$a 10.1111/j.1538-7836.2010.04036.x $2 doi
035    __
$a (PubMed)20735727
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Rulcova, A $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University in Prague, Heyrovskeho, Hradec Kralove
245    10
$a Stereoselective interactions of warfarin enantiomers with the pregnane X nuclear receptor in gene regulation of major drug-metabolizing cytochrome P450 enzymes / $c A. Rulcova, I. Prokopova, L. Krausova, M. Bitman, R. Vrzal, Z. Dvorak, J. Blahos, P. Pavek
520    9_
$a UNLABELLED: Background: Warfarin, an antagonist of vitamin K, is an oral coumarin anticoagulant widely used to control and prevent thromboembolic disorders. Warfarin is clinically available as a racemic mixture of R- and S-warfarin. The S-enantiomer has three to five times greater anticoagulation potency than its optical congener. Recently, vitamin K2 function has been proposed via the pregnane X receptor (PXR) in osteocytes. PXR acts as a xenobiotic sensor that controls expression of many genes involved in drug/xenobiotic metabolic clearance. OBJECTIVE: The aim was to examine whether enantiomers of warfarin stereoselectively interact with PXR to up-regulate main drug/xenobiotic-metabolizing enzymes of the cytochrome P450 superfamily. METHODS: Interactions of warfarin enantiomers with PXR were tested by gene reporter assays and time-resolved fluorescence resonance energy transfer technology (TR-FRET) ligand binding assay. Up-regulation of PXR-target gene mRNAs by warfarin enantiomers was studied using semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) in primary human hepatocytes. RESULTS: We found that R-warfarin interacts with the PXR nuclear receptor. Consistently, R-warfarin significantly induced CYP3A4 and CYP2C9 mRNAs in cultures of primary human hepatocytes or in LS174T intestinal cells. On the other hand, S-warfarin is a less potent inducer of PXR-target genes in human hepatocytes and activates PXR only at supraphysiological concentrations. In addition, we showed that racemic 10- and 4'-hydroxywarfarins are also highly potent PXR ligands and inducers of CYP3A4 and CYP2C9 mRNA in human hepatocytes. CONCLUSION: We showed that R-warfarin can significantly up-regulate major drug-metabolizing enzymes CYP3A4 and CYP2C9 in the liver and thus may cause drug-drug interactions (DDI) with co-administered drugs. The results warrant reconsideration of racemic warfarin usage in clinics.
650    _2
$a antikoagulancia $x chemie $x farmakologie $7 D000925
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a systém (enzymů) cytochromů P-450 $x genetika $7 D003577
650    _2
$a rezonanční přenos fluorescenční energie $7 D031541
650    _2
$a regulace genové exprese enzymů $x účinky léků $7 D015971
650    _2
$a reportérové geny $7 D017930
650    _2
$a lidé $7 D006801
650    _2
$a steroidní receptory $x účinky léků $7 D011987
650    _2
$a polymerázová řetězová reakce s reverzní transkripcí $7 D020133
650    _2
$a stereoizomerie $7 D013237
650    _2
$a aktivace transkripce $7 D015533
650    _2
$a techniky dvojhybridového systému $7 D020798
650    _2
$a upregulace $x účinky léků $7 D015854
650    _2
$a warfarin $x chemie $x farmakologie $7 D014859
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Prokopova, I $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University in Prague, Heyrovskeho, Hradec Kralove
700    1_
$a Krausová, L. $7 _AN046283 $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University in Prague, Heyrovskeho, Hradec Kralove
700    1_
$a Bitman, Michal $7 xx0330075 $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University in Prague, Heyrovskeho, Hradec Kralove
700    1_
$a Vrzal, Radim $7 xx0118949 $u Department of Cell Biology and Genetics, Faculty of Science, Palacky University in Olomouc, Slechtitelu, Olomouc
700    1_
$a Dvořák, Zdeněk, $d 1974- $7 xx0118950 $u Department of Cell Biology and Genetics, Faculty of Science, Palacky University in Olomouc, Slechtitelu, Olomouc
700    0_
$a Blahoš, Jaroslav $7 xx0179439 $u Laboratory of Molecular Pharmacology, Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Videnska, Prague, Czech Republic
700    1_
$a Pávek, Petr $7 xx0093070 $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University in Prague, Heyrovskeho, Hradec Kralove
773    0_
$w MED00007070 $t Journal of thrombosis and haemostasis $x 1538-7836 $g Roč. 8, č. 12 (2010), s. 2708-2717
856    41
$u https://pubmed.ncbi.nlm.nih.gov/20735727 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120816 $b ABA008
991    __
$a 20250318105628 $b ABA008
999    __
$a ok $b bmc $g 949417 $s 784721
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2010 $b 8 $c 12 $d 2708-2717 $i 1538-7836 $m Journal of thrombosis and haemostasis $n J Thromb Haemost $x MED00007070
LZP    __
$b NLK112 $a Pubmed-20120816/11/02

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...